Dr. Greten on Promising Immunotherapy Agents in HCC

Tim F. Greten, MD
Published: Friday, May 19, 2017



Tim F. Greten, MD, senior investigator thoracic and gastrointestinal oncology branch, head, gastrointestinal malignancy section, National Cancer Institute, discusses promising immunotherapy agents being investigated in hepatocellular carcinoma (HCC).

The immunotherapy that is furthest developed in this space is nivolumab (Opdivo), which is being investigated in a phase III study, explains Greten.
,br> Additionally, cell-based therapies are being looked at but they are harder to investigate as there are very little data to analyze, states Greten.

Chimeric antigen receptor (CAR) T-cell therapy has not been very successful in solid cancers but it is 1 of the future areas that will be studied for patients with HCC.

SELECTED
LANGUAGE


Tim F. Greten, MD, senior investigator thoracic and gastrointestinal oncology branch, head, gastrointestinal malignancy section, National Cancer Institute, discusses promising immunotherapy agents being investigated in hepatocellular carcinoma (HCC).

The immunotherapy that is furthest developed in this space is nivolumab (Opdivo), which is being investigated in a phase III study, explains Greten.
,br> Additionally, cell-based therapies are being looked at but they are harder to investigate as there are very little data to analyze, states Greten.

Chimeric antigen receptor (CAR) T-cell therapy has not been very successful in solid cancers but it is 1 of the future areas that will be studied for patients with HCC.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x